Sa1390: THE EFFICACY OF ELBASVIR/GRAZOPREVIR FIXED-DOSE COMBINATION FOR 8 WEEKS IN HCV TREATMENT AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN TREATMENT-NAIVE, NON-CIRRHOTIC, GENOTYPE 4-INFECTED PATIENTS (ELEGANT-4)

Detalles Bibliográficos
Autores principales: AlEid, Ahmad, Balkhi, Areej Al, Alqutub, Adel, Abbarh, Shahem, Allehibi, Abed, Almtawa, Abdullah, Alotaibi, Nawwaf, Alghamdi, Ahmed G., AlGhamdi, Adel, Alamr, Abdulrahman, Ahmad, Shameem, Alsayari, Khalid, AlIbrahim, Bashaar, Khathlan, Abdullah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AGA Institute. Published by Elsevier Inc. 2022
Materias:
AASLD Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212490/
http://dx.doi.org/10.1016/S0016-5085(22)63449-8
_version_ 1784730607611281408
author AlEid, Ahmad
Balkhi, Areej Al
Alqutub, Adel
Abbarh, Shahem
Allehibi, Abed
Almtawa, Abdullah
Alotaibi, Nawwaf
Alghamdi, Ahmed G.
AlGhamdi, Adel
Alamr, Abdulrahman
Ahmad, Shameem
Alsayari, Khalid
AlIbrahim, Bashaar
Khathlan, Abdullah
author_facet AlEid, Ahmad
Balkhi, Areej Al
Alqutub, Adel
Abbarh, Shahem
Allehibi, Abed
Almtawa, Abdullah
Alotaibi, Nawwaf
Alghamdi, Ahmed G.
AlGhamdi, Adel
Alamr, Abdulrahman
Ahmad, Shameem
Alsayari, Khalid
AlIbrahim, Bashaar
Khathlan, Abdullah
author_sort AlEid, Ahmad
collection PubMed
description
format Online
Article
Text
id pubmed-9212490
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AGA Institute. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-92124902022-06-22 Sa1390: THE EFFICACY OF ELBASVIR/GRAZOPREVIR FIXED-DOSE COMBINATION FOR 8 WEEKS IN HCV TREATMENT AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN TREATMENT-NAIVE, NON-CIRRHOTIC, GENOTYPE 4-INFECTED PATIENTS (ELEGANT-4) AlEid, Ahmad Balkhi, Areej Al Alqutub, Adel Abbarh, Shahem Allehibi, Abed Almtawa, Abdullah Alotaibi, Nawwaf Alghamdi, Ahmed G. AlGhamdi, Adel Alamr, Abdulrahman Ahmad, Shameem Alsayari, Khalid AlIbrahim, Bashaar Khathlan, Abdullah Gastroenterology AASLD Abstracts AGA Institute. Published by Elsevier Inc. 2022-05 2022-06-16 /pmc/articles/PMC9212490/ http://dx.doi.org/10.1016/S0016-5085(22)63449-8 Text en Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle AASLD Abstracts
AlEid, Ahmad
Balkhi, Areej Al
Alqutub, Adel
Abbarh, Shahem
Allehibi, Abed
Almtawa, Abdullah
Alotaibi, Nawwaf
Alghamdi, Ahmed G.
AlGhamdi, Adel
Alamr, Abdulrahman
Ahmad, Shameem
Alsayari, Khalid
AlIbrahim, Bashaar
Khathlan, Abdullah
Sa1390: THE EFFICACY OF ELBASVIR/GRAZOPREVIR FIXED-DOSE COMBINATION FOR 8 WEEKS IN HCV TREATMENT AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN TREATMENT-NAIVE, NON-CIRRHOTIC, GENOTYPE 4-INFECTED PATIENTS (ELEGANT-4)
title Sa1390: THE EFFICACY OF ELBASVIR/GRAZOPREVIR FIXED-DOSE COMBINATION FOR 8 WEEKS IN HCV TREATMENT AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN TREATMENT-NAIVE, NON-CIRRHOTIC, GENOTYPE 4-INFECTED PATIENTS (ELEGANT-4)
title_full Sa1390: THE EFFICACY OF ELBASVIR/GRAZOPREVIR FIXED-DOSE COMBINATION FOR 8 WEEKS IN HCV TREATMENT AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN TREATMENT-NAIVE, NON-CIRRHOTIC, GENOTYPE 4-INFECTED PATIENTS (ELEGANT-4)
title_fullStr Sa1390: THE EFFICACY OF ELBASVIR/GRAZOPREVIR FIXED-DOSE COMBINATION FOR 8 WEEKS IN HCV TREATMENT AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN TREATMENT-NAIVE, NON-CIRRHOTIC, GENOTYPE 4-INFECTED PATIENTS (ELEGANT-4)
title_full_unstemmed Sa1390: THE EFFICACY OF ELBASVIR/GRAZOPREVIR FIXED-DOSE COMBINATION FOR 8 WEEKS IN HCV TREATMENT AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN TREATMENT-NAIVE, NON-CIRRHOTIC, GENOTYPE 4-INFECTED PATIENTS (ELEGANT-4)
title_short Sa1390: THE EFFICACY OF ELBASVIR/GRAZOPREVIR FIXED-DOSE COMBINATION FOR 8 WEEKS IN HCV TREATMENT AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN TREATMENT-NAIVE, NON-CIRRHOTIC, GENOTYPE 4-INFECTED PATIENTS (ELEGANT-4)
title_sort sa1390: the efficacy of elbasvir/grazoprevir fixed-dose combination for 8 weeks in hcv treatment and health-related quality of life (hrqol) in treatment-naive, non-cirrhotic, genotype 4-infected patients (elegant-4)
topic AASLD Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212490/
http://dx.doi.org/10.1016/S0016-5085(22)63449-8
work_keys_str_mv AT aleidahmad sa1390theefficacyofelbasvirgrazoprevirfixeddosecombinationfor8weeksinhcvtreatmentandhealthrelatedqualityoflifehrqolintreatmentnaivenoncirrhoticgenotype4infectedpatientselegant4
AT balkhiareejal sa1390theefficacyofelbasvirgrazoprevirfixeddosecombinationfor8weeksinhcvtreatmentandhealthrelatedqualityoflifehrqolintreatmentnaivenoncirrhoticgenotype4infectedpatientselegant4
AT alqutubadel sa1390theefficacyofelbasvirgrazoprevirfixeddosecombinationfor8weeksinhcvtreatmentandhealthrelatedqualityoflifehrqolintreatmentnaivenoncirrhoticgenotype4infectedpatientselegant4
AT abbarhshahem sa1390theefficacyofelbasvirgrazoprevirfixeddosecombinationfor8weeksinhcvtreatmentandhealthrelatedqualityoflifehrqolintreatmentnaivenoncirrhoticgenotype4infectedpatientselegant4
AT allehibiabed sa1390theefficacyofelbasvirgrazoprevirfixeddosecombinationfor8weeksinhcvtreatmentandhealthrelatedqualityoflifehrqolintreatmentnaivenoncirrhoticgenotype4infectedpatientselegant4
AT almtawaabdullah sa1390theefficacyofelbasvirgrazoprevirfixeddosecombinationfor8weeksinhcvtreatmentandhealthrelatedqualityoflifehrqolintreatmentnaivenoncirrhoticgenotype4infectedpatientselegant4
AT alotaibinawwaf sa1390theefficacyofelbasvirgrazoprevirfixeddosecombinationfor8weeksinhcvtreatmentandhealthrelatedqualityoflifehrqolintreatmentnaivenoncirrhoticgenotype4infectedpatientselegant4
AT alghamdiahmedg sa1390theefficacyofelbasvirgrazoprevirfixeddosecombinationfor8weeksinhcvtreatmentandhealthrelatedqualityoflifehrqolintreatmentnaivenoncirrhoticgenotype4infectedpatientselegant4
AT alghamdiadel sa1390theefficacyofelbasvirgrazoprevirfixeddosecombinationfor8weeksinhcvtreatmentandhealthrelatedqualityoflifehrqolintreatmentnaivenoncirrhoticgenotype4infectedpatientselegant4
AT alamrabdulrahman sa1390theefficacyofelbasvirgrazoprevirfixeddosecombinationfor8weeksinhcvtreatmentandhealthrelatedqualityoflifehrqolintreatmentnaivenoncirrhoticgenotype4infectedpatientselegant4
AT ahmadshameem sa1390theefficacyofelbasvirgrazoprevirfixeddosecombinationfor8weeksinhcvtreatmentandhealthrelatedqualityoflifehrqolintreatmentnaivenoncirrhoticgenotype4infectedpatientselegant4
AT alsayarikhalid sa1390theefficacyofelbasvirgrazoprevirfixeddosecombinationfor8weeksinhcvtreatmentandhealthrelatedqualityoflifehrqolintreatmentnaivenoncirrhoticgenotype4infectedpatientselegant4
AT alibrahimbashaar sa1390theefficacyofelbasvirgrazoprevirfixeddosecombinationfor8weeksinhcvtreatmentandhealthrelatedqualityoflifehrqolintreatmentnaivenoncirrhoticgenotype4infectedpatientselegant4
AT khathlanabdullah sa1390theefficacyofelbasvirgrazoprevirfixeddosecombinationfor8weeksinhcvtreatmentandhealthrelatedqualityoflifehrqolintreatmentnaivenoncirrhoticgenotype4infectedpatientselegant4

Ejemplares similares